🔗 Share this article

As America continues making sweeping revisions to its vaccination schedules, one figure appears in a surprising turn: Dr. Tracy Beth Høeg, a Danish American sports physician and public health researcher who first made her name by casting doubt on COVID-19 vaccinations during the global health crisis and has focused upon potential deaths following Covid vaccination in her brief tenure at the US Food and Drug Administration (FDA).

Planned Overhauls to Pediatric Immunization Schedule

Agency leaders had intended to announce radical revisions to the pediatric vaccination calendar earlier this month, bringing the US with the Danish national calendar, according to reports – a significant shift that would put the US at odds with a large portion of the international standard with no evidence for public health gain. The planned update has been delayed until the next year.

In place of the director of the vaccine center, Tracy Beth Høeg is set to speak at the event. She was recently named interim head of the FDA’s CDER, the fifth individual to head the division this year.

A Shift at the Agency

This interim role may indicate a tighter collaboration between the pharmaceutical and vaccine branches as Dr. Høeg and Dr. Prasad strengthen their influence at the FDA – and it suggests a greater focus upon rolling back long-standing immunizations at the FDA.

Dr. Høeg has frequently advocated for ending specific childhood vaccine recommendations in the US so as to align more similar to the Danish model, a country with comprehensive healthcare and a citizenry roughly the size of Wisconsin’s.

In her initial public appearances, she has persisted in emphasizing on immunizations – usually the purview of Prasad, head of the FDA’s CBER – rather than drug regulation.

Questions Over Background

The appointee has no obvious background in medication creation, approval processes or management, which has been standard for past leaders of the CBER. She has served at the FDA as a senior adviser to the agency head and CBER since March.

“She appears not to have the necessary background” for leading the drug-regulation department, remarked Dr. Jonathan Howard. “She’s never run a randomized controlled trial. She is not versed in running a major agency. She has no expertise in drug approvals.”

Former heads of CBER would “be deeply familiar with laws and regulations and the underlying principles of pharmaceutical innovation”, noted Dr. Janet Woodcock. “Clearly, she doesn’t have the kind of background that previous people who ran the center have had.”

The drug center has an immense workload at the agency, she stated.

“Everybody just pays attention on the novel medication approvals, but the off-patent medication office approves numerous generic medications. There is also a biosimilars program, non-prescription drug unit and so forth, and every single one must be looked after,” Dr. Woodcock explained. “The area you neglect, that’s the thing that I always told people is going to bite you.”

Additionally, a major management element to the role, which oversees more than 5,000 employees. “It’s a enormous administrative position, if you perform it correctly,” she added.

Response and Disputed Programs

Regarding inquiries about Høeg’s qualifications and whether this selection signifies greater collaboration among agency officials on vaccines, a press secretary responded that the “inquiries stem from inaccurate presumptions”.

“Her experience matches the functions of her job,” the spokesperson stated, citing the time Høeg spent counseling the FDA commissioner on “drug safety and oversight research, including predictive safety algorithms and immunization monitoring”.

As the temporary head, Dr. Høeg assumes responsibility for the agency head's controversial fast-track approval initiative, a disputed expedited drug-approval program that allegedly troubled her former heads. “By what process are these medications being selected for this expedited pathway? Who takes the calls?” Dr. Howard questioned. “There’s a lot of confidentiality occurring at the agency right now.”

In general, he remarked, “the Food and Drug Administration looks to be trending towards laxer regulations of most medications, with the exception of vaccines.”

Public Track Record on Immunizations

With vaccines, Dr. Høeg has a more established, if problematic, history, some experts said. She published a analysis using non-validated public submissions to estimate the rate of heart inflammation following COVID-19 vaccination. She counseled the state of Florida top health official Joseph Ladapo, who allegedly have altered data to indicate Covid vaccinations are pose a greater threat than they are.

Part of her “wish list” for the incoming federal leadership included revising rules for novel immunizations and halting “unnecessary” vaccines, she stated following the vote on a podcast. At the agency, Høeg has reportedly proposed barring adolescent males from obtaining Covid vaccines.

“She is an thorough true believer who begins with her preconceived notions and works backwards to accommodate the evidence in a extremely disingenuous, fraudulent manner,” Howard stated.

Taking Control and a “Campaign of Retribution”

Høeg became part of fellow contrarians, {like|